IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. August 10, 2026

    Drugmakers Lose 2nd Bid To Appeal Ex-Prosecutor DQ Rebuff

    A former Connecticut prosecutor and his current firm Lowey Dannenberg PC can keep representing insurers Humana Inc. and Molina Healthcare Inc. in an antitrust lawsuit against generic-drug makers, after the judge overseeing the multidistrict litigation rejected a second attempt to appeal her denial of disqualification.

  2. August 07, 2026

    Glenmark's $29.6M Generics Price-Fixing Deal Gets 1st OK

    A Connecticut federal court on Thursday gave a preliminary OK to a settlement between a coalition of 48 states and territories and drugmaker Glenmark Pharmaceuticals Ltd. that would pay out more than $29.6 million in restitution to eligible consumers and the coalition.

  3. August 06, 2026

    Judge Sets Feb. Trial In States' Generics Price-Fixing Suit

    A Connecticut federal judge has set a February trial date on claims from dozens of state attorneys general that generic-drug makers conspired to artificially inflate the prices of generic topical drugs.

  4. August 05, 2026

    Drug Cos. Can't Trim Humana's Price-Fix Claims In Bellwether

    A Pennsylvania federal judge on Tuesday denied a bid by a number of generic drug manufacturers to dismiss two antitrust claims brought by health insurer Humana Inc. from an upcoming bellwether trial in long-running antitrust multidistrict litigation, finding they were brought within the statute of limitations.

  5. August 03, 2026

    Sandoz Settles States' Generics Price-Fixing Cases For $450M

    Sandoz reached a settlement with a coalition of state enforcers on Monday, agreeing to pay $450 million to end claims against it in several cases targeting alleged price-fixing in the generic-drug industry.

  6. July 29, 2026

    Health Economist's Report Cleared For Generic-Drug MDL

    The Pennsylvania federal judge overseeing the multidistrict litigation over generic-drug price-fixing claims has ruled that Humana's health economist's expert report can be admitted into evidence, rejecting several pharmaceutical companies' argument that his findings were based on a flawed methodology.

  7. July 28, 2026

    Teva Can't 'Literally Whine' Of Being Held To DOJ Admissions

    A Pennsylvania federal judge has taken Teva to task for trying to avoid being held to its admissions of price-fixing in a $225 million settlement with the U.S. Department of Justice, ruling that Humana can use those admissions in one of the first bellwether trials in sprawling multidistrict litigation.

  8. July 21, 2026

    $152M Health Marketing Ban, $62M Drug MDL Deal And More

    Law360 Healthcare Authority looks at the Federal Trade Commission's $152 million deal resolving allegations against a pair of health insurance marketers, a $62 million deal releasing Pfizer Inc. and other drugmakers from multidistrict litigation over generic-drug prices, and other key resolutions in healthcare litigation over the last week.

  9. July 17, 2026

    Drug Buyers' $62M Generic-Pricing Deal Gets Final OK

    A federal judge granted final approval to wholesalers on settlements worth a total of at least $62 million with Glenmark Pharmaceutical Inc., Pfizer Inc. and Pfizer subsidiary Greenstone LLC over claims the companies colluded with others to keep generic drug prices high, according to court orders.

  10. July 15, 2026

    Glenmark Reaches $29M Deal In Generics Price-Fixing Case

    Glenmark Pharmaceuticals Inc. and 48 states and territories have reached a $29.6 million settlement resolving allegations the company fixed prices in the generic pharmaceuticals market.